Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Global Blood Ther (GBT)

Global Blood Ther (GBT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,631,449
  • Shares Outstanding, K 62,412
  • Annual Sales, $ 123,800 K
  • Annual Income, $ -247,550 K
  • 60-Month Beta 1.00
  • Price/Sales 13.61
  • Price/Cash Flow N/A
  • Price/Book 5.96
Trade GBT with:

Options Overview Details

View History
  • Implied Volatility 60.81%
  • Historical Volatility 45.70%
  • IV Percentile 61%
  • IV Rank 38.43%
  • IV High 92.34% on 08/02/21
  • IV Low 41.13% on 06/09/21
  • Put/Call Vol Ratio 1.32
  • Today's Volume 244
  • Volume Avg (30-Day) 217
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 14,943
  • Open Int (30-Day) 10,188

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -1.10
  • Number of Estimates 14
  • High Estimate -0.93
  • Low Estimate -1.38
  • Prior Year -0.97
  • Growth Rate Est. (year over year) -13.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.77 +2.91%
on 09/16/21
31.06 -14.62%
on 09/03/21
-2.21 (-7.69%)
since 08/23/21
3-Month
25.48 +4.08%
on 08/19/21
37.59 -29.45%
on 06/25/21
-9.16 (-25.67%)
since 06/23/21
52-Week
25.48 +4.08%
on 08/19/21
64.49 -58.88%
on 10/08/20
-27.20 (-50.63%)
since 09/23/20

Most Recent Stories

More News
GBT Announces Participation at the Cantor Global Healthcare Conference

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Cantor Global Healthcare Conference on Monday, September 27, 2021, at 2:40...

GBT : 26.52 (+1.45%)
Sickle Cell Disease Drugs Market: Industry Outlook, Classification, Demand, Regional Analysis and Forecast to 2030

Research Nester released a report titled which delivers a detailed overview of the global sickle cell disease drugs market in terms of market segmentation by treatment type, disease type, end-user, and...

EMMA : 1.7000 (-1.73%)
GBT : 26.52 (+1.45%)
SIOX : 2.38 (+2.59%)
IMRA : 4.31 (+1.89%)
BLUE : 18.66 (+3.67%)
VRTX : 185.09 (+0.44%)
GBT Establishes The GBT Foundation to Improve the Health and Well-being of Underserved Patient Communities Around the World

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the launch of The GBT Foundation, a 501(c)(3) organization and source of charitable giving that will work to improve the health and well-being...

GBT : 26.52 (+1.45%)
GBT Announces New Employment Inducement Grants

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on September 1, 2021, the compensation committee of GBT's board of directors granted 20 new employees options to purchase an aggregate...

GBT : 26.52 (+1.45%)
GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 10 Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday,...

GBT : 26.52 (+1.45%)
Global Blood's (GBT) NDA & sNDA for Oxbryta Get Priority Review

The FDA grants priority review to Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to 11 years, as well as to its NDA for a pediatric weight-based formulation of the drug.

VRTX : 185.09 (+0.44%)
GBT : 26.52 (+1.45%)
CRVS : 7.03 (-6.14%)
SPRO : 19.51 (+1.19%)
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta(R) (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11

New Drug Application for Oxbryta dispersible tablets also accepted for priority review

GBT : 26.52 (+1.45%)
Why Is Global Blood (GBT) Down 7.5% Since Last Earnings Report?

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GBT : 26.52 (+1.45%)
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe

Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The drug has seen solid uptake since its launch. However, sole dependence on Oxbryta for growth remains a concern.

NVS : 83.57 (+0.93%)
RHHBY : 46.4200 (+0.67%)
GBT : 26.52 (+1.45%)
EDIT : 62.07 (+5.01%)
GBT Announces New Employment Inducement Grants

Global Blood Therapeutics, Inc.�?�(GBT) (NASDAQ: GBT) today announced that on�?�August 1, 2021, the compensation committee of GBT's board of directors granted 12 new employees restricted stock...

GBT : 26.52 (+1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which...

See More

Key Turning Points

3rd Resistance Point 27.64
2nd Resistance Point 27.21
1st Resistance Point 26.86
Last Price 26.52
1st Support Level 26.08
2nd Support Level 25.65
3rd Support Level 25.30

See More

52-Week High 64.49
Fibonacci 61.8% 49.59
Fibonacci 50% 44.98
Fibonacci 38.2% 40.38
Last Price 26.52
52-Week Low 25.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar